Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy - Wikidata - awgldk - TriplyDB

Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy

Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy

http://www.wikidata.org/entity/Q33660542

about

Management of Membranous Nephropathy in Western Countries Kidney disease: new technologies translate mechanisms to cure Autoantibodies in renal diseases - clinical significance and recent developments in serological detection Antiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous Nephropathy Genetic and epigenetic factors influencing chronic kidney disease Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system.M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.Prevalence of Enhanced Granular Expression of Thrombospondin Type-1 Domain-Containing 7A in the Glomeruli of Japanese Patients with Idiopathic Membranous Nephropathy.Membranous Nephropathy: The Journey Continues …Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy.Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy Membranous Nephropathy: Quantifying Remission Duration on Outcome.Changing the concepts of immune-mediated glomerular diseases through proteomics.Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years.Treatment pattern in patients with idiopathic membranous nephropathy-practices in Sweden at the start of the millennium THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy.Patients With Combined Membranous Nephropathy and Focal Segmental Glomerulosclerosis Have Comparable Clinical and Autoantibody Profiles With Primary Membranous Nephropathy: A Retrospective Observational Study Membranous Nephropathy: A Journey From Bench to Bedside Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy.Prevalence of serum anti M-type phospholipase A2 receptor antibody in primary membranous nephropathy: A single center experience Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab.Recent advances in the understanding of immune-mediated nephrotic syndrome: diagnostic and prognostic implications.The Influence and Role of Microbial Factors in Autoimmune Kidney Diseases: A Systematic Review.Membranous nephropathy: thinking through the therapeutic options.Renal Phospholipase A2 Receptor and the Clinical Features of Idiopathic Membranous Nephropathy.Anti-phospholipase A2 receptor antibody levels at diagnosis predicts spontaneous remission of idiopathic membranous nephropathy.A Proposal for a Serology-Based Approach to Membranous Nephropathy.Membranous nephropathy-one morphologic pattern with different diseases.Treatment of membranous nephropathy: time for a paradigm shift.Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.Serum anti-PLA2R antibody and glomerular PLA2R deposition in Chinese patients with membranous nephropathy: A cross-sectional study.Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy.Utility of Determining Autoantibodies to M-type Phospholipase A2 Receptor in Diagnosing Primary Membranous Nephropathy: An Ideal Setting.Recent Progress in Deciphering the Etiopathogenesis of Primary Membranous Nephropathy.Combined Assessment of Phospholipase A2 Receptor Autoantibodies and Glomerular Deposits in Membranous Nephropathy Clinicopathological characteristics of M-type phospholipase A2 receptor (PLA2R)-related membranous nephropathy in Japanese.Anti-Phospholipase A2 Receptor Autoantibody: A New Biomarker for Primary Membranous Nephropathy.

P2860

Q26740477-0048477E-C76A-4540-816D-259615604AAD Q26825227-E8449323-3A9B-4A6B-AB81-A3209B16B9C9 Q26849664-D4CD3451-CAE2-447B-A189-5D6EDB561079 Q27023372-F43326BF-84DF-4BFD-A8C4-7FB2D9E58850 Q27024548-FE0A6C2A-7801-4A05-9FFC-C57B1D514C34 Q33838866-981B411B-0627-44B2-B201-93B3ECA771BA Q34338687-B821F368-1641-468B-A2C5-F7E88DA6F05F Q34455214-3D4CD4F3-5BCE-4C5B-A8CF-A196A52DCB98 Q34783516-23915100-0647-4E94-9F05-BEC98CB068AC Q35782970-FF839F3F-F6FC-496C-A0E4-A070773C40EF Q35800770-FC724CFC-6FFF-4E69-978B-8F9D2AEAA316 Q36063886-5492023B-1ECB-4ECE-8580-054F5ABBFED4 Q36104805-381ED437-B607-4466-96EF-F9172CB490CB Q36167127-9CA68E94-5B9C-4AC0-AE14-DA42EC7B217C Q36201993-6EBC65F4-C6CD-4111-A2CD-7A0615EFDC8F Q36296621-B1E7171C-0E2E-480A-AA60-80192EF190D8 Q36689205-9811D436-CEE5-49F7-977C-5B12D67B4549 Q36764775-59404E06-5A2E-4429-BD46-24CD06216005 Q36849177-3CB3040F-DCAD-4466-8520-204FCEDEB7B3 Q36992978-DE3C4DD5-2059-4E08-9F37-CCFC05007CF7 Q37038576-5807A6A5-D73C-4562-BEEE-A893365DE206 Q37042246-4FEFED3E-F156-4387-BAD4-428E61BF2970 Q37135113-32A58D53-615E-499E-9261-597D4C74D8BA Q37475696-15695516-6A3D-430F-8420-DDEDF9E78F8E Q38371343-FCBBF019-B716-4BF2-A1B1-280482F3558A Q38528984-959AF03F-7DD0-4FB4-A2AD-EEF775C7141E Q38733002-6579D0BA-1BAF-456C-B370-8C4739EB05EB Q38842914-F10CE925-FDB0-4F48-AEF0-7B8949868A04 Q38843422-FD54323D-4EAC-47D1-9039-1378022A440B Q38989854-DA00FAC4-005F-4025-9B25-846484B1CE94 Q39337229-15361455-9DFA-4322-B51F-6EF2F88A775F Q39410091-55FE8CB3-6E7F-4CCD-A3F9-C302086738D8 Q40663445-C158296A-6613-4714-97B3-BAA8B8E59AB1 Q41083693-343D2EAE-93DF-446F-AEF9-C84F8EF3384D Q41123392-C7DD94F5-9D94-4397-ADA3-BC9569AEA4C3 Q41513734-EB2CB575-3D4F-455A-9872-742BC5AF64F6 Q41622450-760722BF-F42F-426A-9FE0-44DDF78FC9DC Q41645471-5665AA92-A9B9-428D-A356-C757F7EC28FB Q41709119-168C442D-5A79-4BFA-B7F7-AFD67545BE6A Q42286490-CE113CEB-C57C-4622-8A1F-1F9820FDBC68

P2860

Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy

http://www.wikidata.org/entity/Q33660542

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Phospholipase A2 receptor auto ...... primary membranous nephropathy

@ast

Phospholipase A2 receptor auto ...... primary membranous nephropathy

@en

type

label

Phospholipase A2 receptor auto ...... primary membranous nephropathy

@ast

Phospholipase A2 receptor auto ...... primary membranous nephropathy

@en

prefLabel

Phospholipase A2 receptor auto ...... primary membranous nephropathy

@ast

Phospholipase A2 receptor auto ...... primary membranous nephropathy

@en

P1433

Q33660542-9F22E63C-AE21-4942-97C6-47D869FA4621

P1476

Q33660542-21E9E450-3318-4D07-AB30-211AA331473D

P2093

Q33660542-2821AD25-8C8C-42D8-ACB4-C8BF57CFE534

Q33660542-5A48BA65-00CF-4AC9-BC65-B108DF3349C1

Q33660542-8A2A5C90-5DA2-43C8-AEE3-678344C55AEB

Q33660542-E270EB9A-83D6-4AC9-AB74-F1C98B7595C1

Q33660542-EA261C76-A413-4E55-A4CF-068A70D21515

P2860

Q33660542-1C22F398-F8D8-4D67-80A5-64F9046E6619

Q33660542-315D9133-8E34-4C9E-B8A9-4CF9598A9B22

Q33660542-38353919-ACFE-4CFF-B62B-FE4771124429

Q33660542-4AC3C35B-FCEC-4131-86C1-68533493FFDB

Q33660542-557EDA6D-F92F-462B-B30E-84D7FDC10F13

Q33660542-63DB4D6E-4D24-49DF-975A-7D072CA45861

Q33660542-AD5F137A-B6C6-47E3-BDCA-188BAF1A04D3

Q33660542-B056A791-C0F9-4B4E-9427-112E1A1AE0FF

Q33660542-C4E4A5A2-33BD-4C48-8E37-24FCD7818D77

Q33660542-D084FE9E-1739-4781-A0A0-452085A052C0

P304

Q33660542-9A7C794A-1C97-4BFE-B340-319C48F2184C

P31

Q33660542-F4B44E12-F5C0-484F-B094-EA79D4B3B067

Q33660542-b0f29c89-eea1-4da3-a262-83647db038fd

P356

Q33660542-4DFE4A5D-81E6-43B1-B98E-E60F6BE15BAA

P433

Q33660542-991EBC8F-FAA1-40BA-9E71-ACEC5DA0ADAB

P478

Q33660542-869C7CD5-ABA7-4F33-9859-0F6E92C932F6

P50

Q33660542-D63FA5E0-FA78-4BFF-AFCD-2288CBFE5DAB

P577

Q33660542-A19593C9-6390-48FA-83D1-C20DD70E8560

P698

Q33660542-D0D4F1FD-2BCE-4CF6-B0A9-D7017B30BC01

P921

Q33660542-BC7787B7-DD12-4DA1-82A0-BC0DC051289E

P932

Q33660542-210189A2-805F-4F54-8CE1-3CABB45A7DFD

P356

P1433

Journal of the American Society of Nephrology

P1476

Phospholipase A2 receptor auto ...... primary membranous nephropathy

@en

P2093

Elion Hoxha

http://www.w3.org/2001/XMLSchema#string

Gunther Zahner

http://www.w3.org/2001/XMLSchema#string

Ina Thiele

http://www.w3.org/2001/XMLSchema#string

Rolf A K Stahl

http://www.w3.org/2001/XMLSchema#string

Ulf Panzer

http://www.w3.org/2001/XMLSchema#string

P2860

M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy

A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.

Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy

The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.

Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy

Rituximab in idiopathic membranous nephropathy.

Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy.

Treatment of idiopathic membranous nephropathy.

Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy

Experimental membranous glomerulonephritis in rats. Quantitative studies of glomerular immune deposit formation in isolated glomeruli and whole animals

P304

1357-1366

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2013040430

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Sigrid Harendza

P577

2014-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24610926

http://www.w3.org/2001/XMLSchema#string

P921

P932

4033365

http://www.w3.org/2001/XMLSchema#string